IRIS
Aghemo, Alessio Michele Goffredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.815
AS - Asia 8.555
EU - Europa 2.784
SA - Sud America 1.520
AF - Africa 414
Continente sconosciuto - Info sul continente non disponibili 268
OC - Oceania 19
Totale 30.375
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.416
SG - Singapore 5.368
CN - Cina 1.337
BR - Brasile 1.246
VN - Vietnam 803
IT - Italia 707
FI - Finlandia 445
IE - Irlanda 327
HK - Hong Kong 272
NG - Nigeria 272
DE - Germania 263
CA - Canada 232
GB - Regno Unito 214
FR - Francia 202
IN - India 163
NL - Olanda 143
AR - Argentina 109
SE - Svezia 109
RU - Federazione Russa 86
BD - Bangladesh 79
TR - Turchia 73
MX - Messico 66
IQ - Iraq 56
ID - Indonesia 50
IL - Israele 50
BE - Belgio 45
JP - Giappone 40
UA - Ucraina 40
EC - Ecuador 38
CO - Colombia 37
PK - Pakistan 36
ES - Italia 35
PL - Polonia 33
EG - Egitto 31
PH - Filippine 31
ZA - Sudafrica 30
VE - Venezuela 29
KE - Kenya 22
MK - Macedonia 20
IR - Iran 19
JM - Giamaica 19
JO - Giordania 19
UZ - Uzbekistan 19
CL - Cile 18
CR - Costa Rica 16
MA - Marocco 16
NP - Nepal 16
PY - Paraguay 16
AU - Australia 15
DZ - Algeria 14
MY - Malesia 14
SA - Arabia Saudita 14
AE - Emirati Arabi Uniti 13
RO - Romania 13
CZ - Repubblica Ceca 12
HN - Honduras 12
PE - Perù 12
KR - Corea 11
AL - Albania 10
AZ - Azerbaigian 10
CH - Svizzera 9
AT - Austria 8
KZ - Kazakistan 8
LT - Lituania 8
TN - Tunisia 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
ET - Etiopia 7
GR - Grecia 7
OM - Oman 7
PA - Panama 7
RS - Serbia 7
TT - Trinidad e Tobago 7
A2 - ???statistics.table.value.countryCode.A2??? 6
BB - Barbados 6
BG - Bulgaria 6
GT - Guatemala 6
LB - Libano 6
BS - Bahamas 5
MD - Moldavia 5
NI - Nicaragua 5
TH - Thailandia 5
TW - Taiwan 5
DK - Danimarca 4
EE - Estonia 4
HU - Ungheria 4
LV - Lettonia 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BO - Bolivia 3
KW - Kuwait 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
PT - Portogallo 3
BW - Botswana 2
GD - Grenada 2
GP - Guadalupe 2
GY - Guiana 2
Totale 30.068
Salva come PNG Salva come JPEG
Città #
Singapore 2.541
Chandler 1.920
Wilmington 1.656
Ashburn 1.002
San Jose 847
The Dalles 729
San Mateo 689
Dallas 603
Ann Arbor 530
Shanghai 529
Council Bluffs 453
Helsinki 441
New York 406
Boardman 379
Beijing 369
Dublin 323
Leawood 310
Princeton 306
Lawrence 288
Milan 278
Benin City 271
Ho Chi Minh City 260
Hong Kong 249
Santa Clara 237
Hanoi 224
Paris 161
Los Angeles 160
Woodbridge 137
Fairfield 134
Phoenix 129
Amsterdam 115
São Paulo 115
Rome 112
Toronto 104
Seattle 88
London 79
Columbus 69
San Diego 64
Buffalo 49
Brooklyn 48
Orem 47
Houston 46
Chicago 45
Da Nang 44
Brussels 43
Rio de Janeiro 42
Atlanta 40
Kocaeli 39
Falkenstein 38
Philadelphia 38
Norwalk 36
Miami 34
Tokyo 33
The Bronx 32
Haiphong 29
Moscow 29
Naples 29
San Francisco 29
Charlotte 28
Falls Church 27
Pune 27
Queens 27
Boston 26
Curitiba 26
Belo Horizonte 25
Las Vegas 25
Warsaw 25
Chennai 24
Denver 24
Manchester 24
Frankfurt am Main 23
Mexico City 23
Baghdad 21
Montreal 21
Porto Alegre 20
Brasília 19
Figino 19
Nairobi 19
Washington 19
Detroit 18
Louisville 17
Newark 17
Sacramento 17
Stockholm 17
Hải Dương 16
Amman 15
Austin 15
Cambridge 15
Campinas 15
Monmouth Junction 15
Salvador 15
Turin 15
Assago 14
Des Moines 14
Fortaleza 14
Johannesburg 14
Mumbai 14
Munich 14
North Bergen 14
Tashkent 14
Totale 18.888
Salva come PNG Salva come JPEG
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 232
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? 216
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 178
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 167
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 158
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis 154
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 154
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 150
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 149
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 141
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 140
A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019 138
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 138
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 137
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 137
Mapping the human genetic architecture of COVID-19 129
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 126
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 125
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 124
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 124
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 124
Daclatasvir for the treatment of chronic hepatitis C 124
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 123
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 123
From current status to optimization of HCV treatment: Recommendations from an expert panel 123
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 122
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 121
The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment 121
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 121
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 120
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 120
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 120
A risk score based on baseline risk factors for predicting mortality in COVID-19 patients 120
Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization 119
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 115
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 115
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 115
Real life experiences in HCV management in 2018 114
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 113
Recommendations for the management of hepatitis C virus infection among people who inject drugs 113
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy 113
Impaired response to interferon-alpha 2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection 112
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 112
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 112
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 111
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 111
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 110
EASL Recommendations on Treatment of Hepatitis C 2014 110
Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease 110
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 110
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 110
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 110
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 109
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 109
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 108
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 108
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 108
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 107
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature 107
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? 106
High mortality in COVID-19 patients with mild respiratory disease 106
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 105
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 105
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 105
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 104
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 104
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 104
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals? 103
COINCIDENCE OF CALCITONIN-GENE-RELATED PEPTIDE IMMUNOREACTIVITY AND TERMINAL FIELDS OF EFFERENTS FROM THE CARDIOVASCULAR PORTION OF THE FASTIGIAL NUCLEUS - PRELIMINARY-REPORT 103
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 102
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 102
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study 102
OSMOREGULATION OF VASOPRESSIN DURING ACUTE LOWERING OF ARTERIAL-PRESSURE BY CLONIDINE IN MODERATE HYPERTENSION 102
Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes 102
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 101
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 101
REGULATION OF VASOPRESSIN SECRETION AFTER ADMINISTRATION OF SODIUM-NITROPRUSSIDE IN HYPERTENSIVES 101
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 101
Safety of vedolizumab in liver transplant recipients: A systematic review 101
Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery 101
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 101
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 100
An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study 99
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 99
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 99
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 99
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 98
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 98
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 98
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies 98
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 98
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 97
Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials 97
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 96
New horizons in hepatitis C antiviral therapy with direct-acting antivirals 96
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 96
The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response 96
Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method 96
Are We Ready to Discontinue Hepatitis B Immunoglobulins to Prevent Hepatitis B and D Recurrence in Liver Transplant Recipients? 96
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 95
Totale 11.603
Salva come PNG Salva come JPEG
Categoria #
all - tutte 189.847
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 189.847
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.535 0 0 0 359 20 21 77 221 121 197 405 114
2022/20234.749 675 211 459 563 430 409 7 418 877 362 273 65
2023/20242.682 184 263 549 130 103 422 149 153 38 46 250 395
2024/20253.997 118 102 51 88 96 417 286 500 551 906 459 423
2025/202610.269 1.484 628 640 876 225 408 3.173 638 560 619 351 667
2026/20273.904 792 973 1.593 546 0 0 0 0 0 0 0 0
Totale 30.375